Cresilon Completes First Phase Preclinical Study of Hemostatic Gel Technology
The study results can help advance the treatment of traumatic brain injury (TBI) for both military service members and civilians.
Cresilon Inc., a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, has completed the first phase of a preclinical study conducted with the Walter Reed Army Institute of Research (WRAIR). The preclinical study was performed under a Cooperative Research and Development Agreement between WRAIR and Cresilon to advance the treatment of traumatic brain injury (TBI) for both military service members and civilians.
"TBIs significantly impact the health, preparedness, and resilience of military personnel," said Dr. Anke Scultetus, WRAIR. "The results of this study with Cresilon are encouraging as we work to deliver solutions for medical personnel and our injured service members."
The study evaluated the safety and efficacy of Cresilon's proprietary hemostatic hydrogel in a model of penetrating TBI. Preliminary findings from the preclinical study demonstrated promising results in the ability of Cresilon's plant-based hemostatic gel to control bleeding when applied to a wound and to provide neuroprotection following a penetrating TBI.
"We are honored to be collaborating with WRAIR in studying our innovative hemostatic gel technology as a potential solution to address a critical unmet medical need for both military service members and civilians," said Cresilon CEO and Co-Founder Joe Landolina. "We look forward to continuing our partnership with the WRAIR and the next phases of this study, which could potentially yield a field and prehospital treatment that may not only save lives but also minimize brain damage when a penetrating head injury occurs."
WRAIR will pursue more studies using Cresilon's hemostatic hydrogel. This hemostatic gel is the first-ever technology to blend refined plant polymers to create a mechanical barrier when applied to wounds. Cresilon's plant-based hemostatic gel comes in a pre-filled syringe and is designed to provide a fast, effective, and easy-to-use solution to stop and control severe bleeding at the point of care. The formula does not need special preparation or storage conditions.
Cresilon also recently submitted a 510(k) application to the U.S. FDA for TRAUMAGEL, which is intended to be used in moderate to severe external bleeding.
Last year, the company received FDA 510(k) clearance for Cresilon Hemostatic Gel (CHG), which is intended for use in the local management of bleeding wounds such as minor cuts, lacerations, and abrasions.
July 12, 2024
